| KI | Kinase inhibitors |
| MKI | Multi kinase inhibitor |
| RTK | Receptor tyrosine kinase |
| VEGF | Vascular Endothelial Growth Factor |
| TTFields | Tumor Treatment Fields |
| PKA | Cyclic-AMP-dependent protein kinase |
| EGFR | Epidermal Growth Factor Receptor |
| FGFR | Fibroblast Growth Factor Receptor |
| EGFR | Epidermal Growth Factor Receptor |
| NSCLS | Non small cell lung cancer |
| TGF-α | Transforming Growth Factor alpha |
| HB-EGF | Heparin-binding EGF-like Growth Factor |
| MAPK | Mitogen-Activated Protein Kinase |
| NSCLC | Non Small Cell Lung Cancer |
| OS | Overall Survival |
| BBB | Blood–Brain Barrier |
| PDGF | Platelet-Derived Growth Factor |
| PDGFR | Platelet-Derived Growth Factor Receptor |
| VEGFR1-3 | Vascular Endothelial Growth Factor Receptors 1, 2 and 3 |
| TIS | Therapy-Induced Senescence |
| GSC | Glioma Stem Cell |
| ROS | Reactive Oxygen Species |
| ATM | Ataxia Telangectasia Mutated |
| HIF 1 α | Hypoxia inducible factor 1α |
| CDKN1A | Cyclin dependent kinase inhibitor 1A |
| FFPE | Formalin fixed paraffin embedded |
| PSAT1 | Phosphoserine aminotransferase 1 |